



For Immediate Release:
November 28, 2005

Contact:
Laura Housman
(508) 389-6618

Genzyme Genetics Enters into Provider Agreement with Preferred Health Care

Westborough, MA, November 28, 2005 – Genzyme Genetics, a division of Genzyme Corporation announced today that it has entered into a multi-year provider participation agreement with Preferred Health Care (PHC), adding Genzyme Genetics to PHC's extensive network of participating physicians, hospitals, and other healthcare professionals. Under the agreement, Genzyme Genetics will provide its full suite of oncology screening, diagnostic and prognostic services, as well as prenatal, reproductive, genetic counseling and women's health offerings to over 60,000 enrollees accessing PHC's network of participating providers. Specific terms of the agreement were not disclosed.

"We are very pleased to be working with PHC to offer enrollees and network participating providers access to Genzyme Genetics' comprehensive offerings. Through our agreement we will provide availability to one of the country's largest laboratories for reproductive and oncology testing. In addition, we will provide access to board-certified genetic experts and pathologists for consultation on difficult cases to members in Lancaster and Chester County," said Michael F. Minahan, Senior Vice President Sales and Marketing, Genzyme Genetics.

About Preferred Health Care

PHC is a provider sponsored managed care network, representing approximately 1100 local physicians, nine hospitals- Brandywine Hospital, Ephrata Community Hospital, Gettysburg Hospital, Heart of Lancaster Regional Medical Center, Jennersville Regional Hospital, Lancaster General Hospital, Lancaster Regional Medical Center, The Women and Babies Hospital, and York Hospital - along with an array of ancillary and tertiary facilities and providers.

About Genzyme Genetics

Genzyme Genetics is driven by its commitment to patients and offers a broad array of testing services for pathology, oncology, prenatal and reproductive medicine. Twenty years of testing expertise utilizing sophisticated technologies has made Genzyme Genetics a leading worldwide provider of high-quality testing services for physicians and their patients. With an extensive network of laboratories across the United States and operations in Europe and Japan, Genzyme Genetics assists thousands of clinicians in providing the best care possible to patients. As a division of Genzyme Corporation, Genzyme Genetics contributes its resources and strengths to one of the world's leading biotechnology companies.

About Genzyme Corporation

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis, cancer and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services and sophisticated biomaterials. Genzyme's commitment to innovation continues today with expanded research into novel approaches to treat cancer, heart disease, and other areas of unmet medical need. More than 7,000 Genzyme employees in offices around the globe serve patients in over 80 countries.